The formulation distinction that changes the entire conversation, and the studies your provider hasn’t mentioned
Full Drug Card → Influenza Vaccine (Maternal)| Feature | Multi-dose vial | Single-dose pre-filled syringe |
|---|---|---|
| Thimerosal (mercury preservative) | 25 mcg ethylmercury per doseUsed to prevent contamination in multi-dose vials | None (preservative-free)Single-use — no preservative required |
| Cost to clinic | LowerWhy most high-volume settings default to this | Slightly higher |
| Disclosed to patient? | Almost never | Only if you ask |
| Thimerosal-free brands (single-dose) | Fluzone Quadrivalent, Fluarix, Flucelvax, AfluriaAll in pre-filled syringe form |
Thimerosal contains ethylmercury — an organic mercury compound that is metabolized and excreted more quickly than methylmercury (the form in fish). This difference is used to reassure patients. What is rarely mentioned: a primate study by Burbacher et al. (2005, Environmental Health Perspectives) found that ethylmercury redistributed to brain tissue at approximately twice the rate of methylmercury. The shorter half-life in blood does not mean less brain exposure. The common comparison — “thimerosal is safer than fish mercury” — is not supported by this study.
At 25 mcg per dose, the thimerosal in a multi-dose flu shot is a direct parenteral (injected) mercury dose. Injected and ingested mercury are not comparable exposures — the bioavailability is fundamentally different.
Goldman and Miller (2013, Human and Experimental Toxicology) analyzed VAERS (Vaccine Adverse Event Reporting System) reports for fetal loss following the 2009 H1N1 influenza campaign. They found a 4,000% increase in fetal-loss reports among pregnant women who received both the H1N1 vaccine and the seasonal influenza vaccine in the same season — the seasonal flu vaccine containing thimerosal.
VAERS reports are self-selected and do not establish causation. But a 4,000% increase in reported fetal losses in a specific exposure group in a specific year is a signal that belongs in the informed consent conversation. It is not disclosed when the flu shot is offered.
This peer-reviewed study, published in the journal Vaccine, used data from the Vaccine Safety Datalink — a CDC-affiliated surveillance system. It found a statistically significant association between influenza vaccination in the first trimester and spontaneous abortion (miscarriage), particularly in women who had also received the influenza vaccine the prior year. The adjusted odds ratio was 7.7 (95% CI 2.2–27.3) for women vaccinated in both the current and prior seasons.
An odds ratio of 7.7 means the study found the rate of miscarriage in this specific group to be approximately 7.7 times higher than in unvaccinated women. The authors concluded the finding was unexpected and required replication. As of 2026, it has not been definitively refuted. It is not disclosed when the flu shot is offered in the first trimester.
Many pregnant women are offered both the multi-dose flu shot and multi-dose RhoGAM (Rh immunoglobulin) at the same 28-week appointment. Multi-dose RhoGAM contains up to 25 mcg of ethylmercury per dose. Receiving both at the same appointment produces a combined parenteral mercury dose of up to 50 mcg. This combination has not been studied for its developmental impact. Neither provider — the OB ordering RhoGAM, the nurse administering the flu shot — typically has visibility into both exposures happening at the same visit.